ARC Training Centre for Personalised Therapeutics Technologies

  • Stewart, Alastair G (Primary Chief Investigator (PCI))
  • Pfleger, Kevin D G (Chief Investigator (CI))
  • Voelcker, Nicolas Hans (Chief Investigator (CI))
  • Pebay, Alice (Chief Investigator (CI))
  • Dottori, Mirella (Chief Investigator (CI))
  • Lee, Peter (Chief Investigator (CI))
  • Elnathan, Roey (Chief Investigator (CI))
  • O'Connor, Andrea J (Chief Investigator (CI))
  • Rodger, Jennifer (Chief Investigator (CI))
  • Palaniswami, Marimuthu S (Chief Investigator (CI))
  • Doyle, Barry (Chief Investigator (CI))
  • Kennedy, Brendan (Chief Investigator (CI))
  • Kameneva, Tatiana (Chief Investigator (CI))
  • Heng, Julian (Chief Investigator (CI))
  • Sercombe, Timothy (Chief Investigator (CI))
  • Pouton, Colin William (Chief Investigator (CI))
  • Zheng, Minghao (Chief Investigator (CI))
  • Mangum, Jonathan E (Chief Investigator (CI))
  • Volery, Thierry (Chief Investigator (CI))
  • Lim, Chwee Teck (Partner Investigator (PI))
  • Herz, Jennifer (Partner Investigator (PI))
  • Baker, Michelle Louise (Partner Investigator (PI))
  • Lipscombe, Richard (Partner Investigator (PI))
  • Anderson, Paul (Partner Investigator (PI))
  • Keenan, Martine (Partner Investigator (PI))
  • Barker, Andrew (Partner Investigator (PI))
  • Shand, Todd (Partner Investigator (PI))
  • Smith, Brigitte (Partner Investigator (PI))
  • Wadsworth, Samuel (Partner Investigator (PI))
  • Tan, Amabel (Partner Investigator (PI))
  • Rush, Robert (Partner Investigator (PI))
  • Gooley, Andrew A (Partner Investigator (PI))
  • Rose, Stephen (Partner Investigator (PI))
  • Nicholson, James (Partner Investigator (PI))
  • Munsie, Megan (Chief Investigator (CI))

Project: Research

Project Description

This project, through training the next generation of biomedical researchers, aims to create and develop in Australia the skills and technology to enable early benefit from the transformative impacts that cell/organ-on-achip technology will have on the medtech/pharma industries. Advancing ineffective medicines into clinical trial costs vast sums of money and lost opportunities, as does using medicines in patients without benefit. Combining microfluidics-based/real-time technologies with personalised medicine should allow us to provide growth opportunities through improved screening of potential therapeutics, and use an individual patient’s cellular and molecular research findings to enable personalised diagnostic and therapeutic decisions.
StatusActive
Effective start/end date11/05/1830/06/23